Plasma beta-hydroxy-beta-methylbutyrate availability after enteral administration during critical illness after trauma : An exploratory study
© 2024 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition..
BACKGROUND: During critical illness skeletal muscle wasting occurs rapidly. Although beta-hydroxy-beta-methylbutyrate (HMB) is a potential treatment to attenuate this process, the plasma appearance and muscle concentration is uncertain.
METHODS: This was an exploratory study nested within a blinded, parallel group, randomized clinical trial in which critically ill patients after trauma received enteral HMB (3 g daily) or placebo. Plasma samples were collected at 0, 60, and 180 min after study supplement administration on day 1. Needle biopsies of the vastus lateralis muscle were collected (baseline and day 7 of the HMB treatment intervention period). An external standard curve was used to calculate HMB concentrations in plasma and muscle.
RESULTS: Data were available for 16 participants (male n = 12 (75%), median [interquartile range] age 50 [29-58] years) who received placebo and 18 participants (male n = 14 (78%), age 49 [34-55] years) who received HMB. Plasma HMB concentrations were similar at baseline but increased after HMB (T = 60 min: placebo 0.60 [0.44-1.31] µM; intervention 51.65 [22.76-64.72] µM). Paired muscle biopsies were collected from 11 participants (placebo n = 7, HMB n = 4). Muscle HMB concentrations were similar at baseline between groups (2.35 [2.17-2.95]; 2.07 [1.78-2.31] µM). For participants in the intervention group who had the repeat biopsy within 4 h of HMB administration, concentrations were greater (7.2 and 12.3 µM) than those who had the repeat biopsy >4 h after HMB (2.7 and 2.1 µM).
CONCLUSION: In this exploratory study, enteral HMB administration increased plasma HMB availability. The small sample size limits interpretation of the muscle HMB findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
JPEN. Journal of parenteral and enteral nutrition - (2024) vom: 24. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wittholz, Kym [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
β‐hydroxy‐β‐methylbutyrate |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/jpen.2622 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370115635 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370115635 | ||
| 003 | DE-627 | ||
| 005 | 20240324235548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jpen.2622 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1345.xml |
| 035 | |a (DE-627)NLM370115635 | ||
| 035 | |a (NLM)38522007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wittholz, Kym |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma beta-hydroxy-beta-methylbutyrate availability after enteral administration during critical illness after trauma |b An exploratory study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. Journal of Parenteral and Enteral Nutrition published by Wiley Periodicals LLC on behalf of American Society for Parenteral and Enteral Nutrition. | ||
| 520 | |a BACKGROUND: During critical illness skeletal muscle wasting occurs rapidly. Although beta-hydroxy-beta-methylbutyrate (HMB) is a potential treatment to attenuate this process, the plasma appearance and muscle concentration is uncertain | ||
| 520 | |a METHODS: This was an exploratory study nested within a blinded, parallel group, randomized clinical trial in which critically ill patients after trauma received enteral HMB (3 g daily) or placebo. Plasma samples were collected at 0, 60, and 180 min after study supplement administration on day 1. Needle biopsies of the vastus lateralis muscle were collected (baseline and day 7 of the HMB treatment intervention period). An external standard curve was used to calculate HMB concentrations in plasma and muscle | ||
| 520 | |a RESULTS: Data were available for 16 participants (male n = 12 (75%), median [interquartile range] age 50 [29-58] years) who received placebo and 18 participants (male n = 14 (78%), age 49 [34-55] years) who received HMB. Plasma HMB concentrations were similar at baseline but increased after HMB (T = 60 min: placebo 0.60 [0.44-1.31] µM; intervention 51.65 [22.76-64.72] µM). Paired muscle biopsies were collected from 11 participants (placebo n = 7, HMB n = 4). Muscle HMB concentrations were similar at baseline between groups (2.35 [2.17-2.95]; 2.07 [1.78-2.31] µM). For participants in the intervention group who had the repeat biopsy within 4 h of HMB administration, concentrations were greater (7.2 and 12.3 µM) than those who had the repeat biopsy >4 h after HMB (2.7 and 2.1 µM) | ||
| 520 | |a CONCLUSION: In this exploratory study, enteral HMB administration increased plasma HMB availability. The small sample size limits interpretation of the muscle HMB findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a critical illness | |
| 650 | 4 | |a enteral nutrition | |
| 650 | 4 | |a nutrition therapy | |
| 650 | 4 | |a skeletal muscle | |
| 650 | 4 | |a β‐hydroxy‐β‐methylbutyrate | |
| 700 | 1 | |a Bongetti, Amy J |e verfasserin |4 aut | |
| 700 | 1 | |a Fetterplace, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Caldow, Marissa K |e verfasserin |4 aut | |
| 700 | 1 | |a Karahalios, Amalia |e verfasserin |4 aut | |
| 700 | 1 | |a De Souza, David P |e verfasserin |4 aut | |
| 700 | 1 | |a Elahee Doomun, Sheik Nadeem |e verfasserin |4 aut | |
| 700 | 1 | |a Rooyackers, Olav |e verfasserin |4 aut | |
| 700 | 1 | |a Koopman, René |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Gordon S |e verfasserin |4 aut | |
| 700 | 1 | |a Ali Abdelhamid, Yasmine |e verfasserin |4 aut | |
| 700 | 1 | |a Deane, Adam M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JPEN. Journal of parenteral and enteral nutrition |d 1978 |g (2024) vom: 24. März |w (DE-627)NLM000294233 |x 1941-2444 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:24 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jpen.2622 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 24 |c 03 | ||